The role of institutional context in the development of the SME biotech sector in Poland by Micek, Grzegorz et al.
Prace Komisji GeoGrafii Przemysłu PolsKieGo TowarzysTwa GeoGraficzneGo
25 2014
grzegorz mIcek
Jagiellonian University, Poland
PaulIne gleadle
Norwich Business School, University of East Anglia, Norwich, United Kingdom
PIotr dawIdko
Jagiellonian University, Poland 
The Role of Institutional Context in the Development 
of the SME Biotech Sector in Poland
Abstract: Whilst Poland is argued to represent one of the largest and most entrepreneurial economies 
in CE with huge potential for development of the SME biotech industry, this sector remains relatively 
underdeveloped. In this paper, we explore reasons for this apparent anomaly, focusing on the inter-
relationships between institutional context and entrepreneurial behaviour. We adopt Smallbone and 
Welter’s (2009a, b) typology (Welter, Smallbone, 2011) of entrepreneurial behaviour in constructing 
a case study of the biotech SME industry in Poland, concluding that the sector faces particular institu-
tional challenges which entrepreneurs react to in a variety of ways. We conclude that Poland presents 
serious obstacles to a knowledge-intensive sector such as biotech. 
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IntroductIon
Biotechnology generally is recognised as a sector in which SME entrepreneurs play 
a major role (e.g. Haslam et al., 2011) and at the same time Poland as a country represents 
one of the largest post-socialist economies in Central Europe (CE)1 and one of the most entre-
preneurial (Estrin, Mickiewicz, 2010). However, in Poland, despite certain favourable condi-
tions which we will discuss later, we see an underdevelopment of the biotech industry, so in 
this paper we explore reasons behind this apparent anomaly. Specifically, we focus on the in-
terrelationships between institutional context and entrepreneurial behaviour of SME biotech 
entrepreneurs in Poland. Hence, in contrast to Welter and Smallbone (2011) and Smallbone 
and Welter (2010), we focus not on manufacturing or trade industries, but on a knowledge-in-
tensive sector, represented by biotechnology. We argue that existing typologies of entrepre-
1  Post-socialist Central European countries refer to, for instance, Poland and Hungary which were not for-
mally a part of the Soviet Union.
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neurial behaviour (which we refer to in the rest of this paper as Welter and Smallbone, 2011) 
do not fully fit the biotechnology industry and, moreover, that typologies of business models 
in biotech (Clarysse et al., 2003) are outdated and do not take into account the institutional 
frameworks of countries in transition. We follow Peng (2000) cited in Welter and Smallbone 
(2011: 116) in arguing that not all companies react to changing institutional context in the 
same way, so presenting different responses to institutional pressures and hence exhibiting 
different types of entrepreneurial behaviour. However, Welter and Smallbone’s (2011: 108) 
study covered examples of companies from mainly former Soviet republics rather than from 
CE post-socialist countries. To summarise, we contribute to the literature by exploring entre-
preneurial behaviour in a knowledge-intensive sector in a CE post-socialist country. This is 
particularly pertinent given Mroczkowski and Elms’s (2009) and Suurna’s (2011) comments 
that little is known about biotech industry development in emerging knowledge-based econ-
omies of CE and that more research is needed on comparative biotechnology development in 
these countries. However, importantly the biotech industry in Poland is not well-developed 
in relation to its potential, so this paper explores the reasons why. We argue that some of 
the reasons for this are to be found in Poland’s institutional obstacles. Whilst Welter and 
Smallbone (2011: 108) see Poland and other accession countries as less challenging environ-
ments for entrepreneurs than some former Soviet republics, we argue that Poland poses par-
ticular institutional problems for the biotech sector as an example of a knowledge-intensive 
industry. In so doing, the paper adopts the following structure.
Firstly, we discuss institutional perspectives and their relationship to theories of entre-
preneurial behaviour. After setting out some key aspects of the biotech industry in Poland, 
we discuss our methodology. Institutional challenges facing the Polish biotech industry then 
provide the background against which we discuss the types of entrepreneurial behaviour in 
the sector. We distinguish three over-arching types of entrepreneurial behaviour with respect 
to the following categories: regulation, business portfolios and funding. Underlying the lat-
ter, we argue there is a strong desire for independence on the part of the entrepreneurs. We 
conclude that the institutional challenges facing Polish biotech industry constitute constraints 
on entrepreneurial behaviour. We turn then to the topic of institutionalism.
InstItutIonal framework
North (1994) developed an institutional perspective which we argue to be a powerful an-
alytical framework to understand economic change. Consequently, we adopt this framework 
to explore the arguably challenging environment of Poland, a country in transition (Welter, 
Smallbone, 2011). North (1990, 1994) frames institutionalism in terms of a combination 
of formal institutions (including at the legal and organisational levels) and informal codes 
of conduct, norms, beliefs and values. Formal rules and institutions that may change over-
night pose a substantial challenge to entrepreneurs, so influencing their behaviour (Welter, 
Smallbone, 2011). For instance, legal frameworks (e.g. detailed regulations governing the 
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calculation of value added tax or eligible costs in EU projects) shape funding systems and 
consequently also the growth of industry. By way of contrast, stable and predictable regula-
tory frameworks through reducing transaction costs, have a direct influence on entrepreneur-
ship behaviour. Hence, deficient legal systems (such as unclear intellectual property rights or 
the lack of specialist commercial and property lawyers), constrain the functioning of formal 
organisations and so hamper the growth of industry.
We argue that excessive changes (both of a positive and of a negative nature) complicate 
institutional systems, leading to a more unpredictable life for entrepreneurs. Our analysis 
adopts an institutional framework in an heuristic fashion. In so doing, we pay close attention 
to the roles of institutions, history and political economies in explaining the challenges facing 
the Polish biotechnology. We believe that institutions provide both opportunities as well as 
constraints in economic development, on an organisational scale and at a more individual 
level, on entrepreneurial behaviour. 
Niosi (2011: 1798) distinguishes four types of institutions important to the biotech-
nology industry: organisations (firms, universities, government departments and research 
institutes, venture capital partnerships), routines (repetitive patterns of actions within or-
ganisations that may cause enormous inertia), norms or customs (patterns of social actions 
based on common attitudes, expectations, beliefs, values etc.) and laws or policies imposed 
by regional, national or EU legislation. Bartholomew (1997, cited by Niosi, 2011: 1803) 
distinguishes eight elements in the institutional structure of biotechnology:
 – the level and patterns of national funding of basic research;
 – the linkages with foreign research institutions; 
 – the national tradition of scientific education;
 – the degree of commercial orientation of research institutions; 
 – labour mobility between university and industry;
 – the venture capital market;
 – the role of government in technology diffusion;
 – technological accumulation in related sectors.
Whilst the focus of the current study is upon entrepreneurial behaviour in the face of 
particular institutional challenges in relation to Poland as an economy in transition, we will 
return to this issue of the sectoral requirements of biotech in our conclusions.
Of particular relevance to countries such as Poland, an observed unwillingness to act as 
an entrepreneur in risk-intensive businesses and transition economies may have deep roots 
in a nation’s communist heritage. In this connection, Estrin and Mickiewicz (2010) point at 
the relatively slow pace of development of informal institutions and their effect on social 
attitudes, notably the low levels of generalised trust. “Thus, trust is an essential prerequisite 
for entrepreneurship but the transition countries share a negative heritage of a system based 
on authoritarian hierarchical organisation and detailed surveillance of all citizens” (Estrin, 
Mickiewicz, 2010: 11).
Estrin and Mickiewicz (2010: 10) mention the lower levels of autonomy and mas-
tery among entrepreneurs that “remain(ed) much weaker in post-communist societies than 
in comparator West European societies in the mid-1990s”. Arguably, this may be a legacy 
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partly of the rigidly hierarchical relationships common between citizens and officials under 
communism. 
Estrin and Mickiewicz (2010: 6–7) list institutional legacies of communism that are not 
conducive to entrepreneurship: “(…) the quality of commercial code, the strength of legal 
enforcement, administrative barriers to entry and to business activities, the prevalence of 
extra-legal payments and a lack of market-supporting institutions”.
According to Sztompka (1996), these communist legacies resulted in attitudes of exces-
sive dependence and conformity. Welter (2011) argues that context is important for under-
standing when, how, and why entrepreneurship happens (or does not happen) and who acts in 
an entrepreneurial fashion. In our paper we look at the business context and the somewhat ne-
glected institutional context (Welter, 2011). We argue that the institutional context in Poland 
remains influenced by its communist legacy. 
entrePreneurIal behavIour 
The majority of entrepreneurship theories focus on the micro-level foundations of en-
trepreneurial behaviour, “taking the external environment (including institutions) as given” 
(Smallbone et al., 2010: 657). Based on empirical research (e.g. Peng, 2003; Manolova et 
al., 2008) we follow Smallbone and Welter (2006) and Smallbone et al. (2010) in arguing 
that such an approach is inappropriate to transition economies, where external influences on 
entrepreneurial behaviour are both enormous and unstable.
We understand entrepreneurial behaviour as being a response to a particular set of ex-
ternal (institutional) environmental conditions. However, we adopt a wide definition of en-
trepreneurial behaviour that encompasses entrepreneurs’ reactions to a volatile or hostile 
external environment, both while setting up or running a business.
The most recent typology of entrepreneurial behaviour in a transition context has been 
provided by Welter and Smallbone (2011). Based on previous studies conducted mainly in 
former Soviet Union republics (Smallbone, Welter, 2009a, 2009b) six types of entrepreneur-
ial responses to institutional framework have been identified. The first type of managerial be-
haviour is called ‘prospecting’ (1) (Peng, 2000: 178) and is used to characterise firms “with 
a changing market, a focus on innovation and change and a flexible organisational structure”. 
Such a strategy of frequent change of products/services cannot be always treated positively, 
but may in some cases constitute a necessary element of survival (Welter, Smallbone, 2011). 
An ‘evasion’ strategy (2) may be the only way to survive for the company, especially in diffi-
cult environments where taxes are high and bribes have to be proffered. ‘Financial bootstrap-
ping’ type (3) refers to a behaviour that is followed under conditions of scarcity of capital 
from formal sources. In such cases, serial entrepreneurship may be necessary just in order to 
accumulate the financial resources to start a business. The fourth type named ‘diversification 
and portfolio entrepreneurship’ (4) may apply to companies that offer additional non-core 
services or products which may contribute to a firm’s revenues in conditions of volatile, 
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unpredictable or scarce demand. The reason behind such diversification quoted by Welter 
and Smallbone (2011: 111) can include making “business success less visible to officials 
and those who may seek to make money from «offering protection»”. The next type (5) of 
entrepreneurial response to external influences is based on developing networks of personal 
contacts (with friends and acquaintances) for business purposes. Finally, type (6), adaptation 
behaviour, is based on the necessity of dealing with complicated administrative regulations 
and laws, and to adapt to these even if doing so may be cumbersome and expensive. Whilst 
we endorse Welter and Smallbone’s (2011) typology, we would suggest that this could be 
re-grouped around three core dimensions of entrepreneurial responses towards: regulations, 
business portfolios and funding (Tab. 1).
Tab. 1. Dimensions of entrepreneurial behaviour
Dimensions of 
entrepreneurial behaviour
Type of entrepreneurial behaviour (Welter, Smallbone, 2011)
Regulations
(Tax) evasion (2)
Networking (5)
Adaptation strategy (6)
Business portfolio
Prospecting behaviour (1) 
Diversification and portfolio entrepreneurship (4)
Funding Financial bootstrapping (3)
Source: own elaboration based on Welter, Smallbone, 2011
We turn next to an overview of the biotech industry in Poland. In this paper, we are fo-
cusing on medical (‘red’) biotechnology industry, the largest branch of the biotech sector in 
Poland. Over half of the Polish biotech companies surveyed by the National Statistical Office 
are involved in medical biotechnology (Nauka i Technika, 2011). We focus on dedicated 
biotechnology firms (DBFs), whose predominant activity, according to the OECD, involves 
the application of biotechnology techniques to produce goods or services and/or to perform 
biotechnology R&D (van Beuzekom, Arundel, 2009).
background to the bIotech Industry In Poland
Poland is argued to be amongst one of the most entrepreneurial countries in CE (Estrin, 
Mickiewicz, 2010). However, whilst the number of firms generally increased sharply in what 
has been described in Poland as “an explosion of entrepreneurship” (Piasecki, Rogut, 1993, 
cited by Smallbone, Welter, 2006) after the liberalising reforms of 1988, there has been 
limited development of the biotech industry compared with some other CE countries such as 
Hungary (Mroczkowski, Elms, 2009). The number of firms meeting the narrow definition of 
dedicated biotech firms is disputed. Mroczkowski and Elms (2009) give this number as en-
compassing 20 firms with 1172 employees at that time, of whom 232 were directly involved 
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in R&D, although according to our own calculations the number of dedicated biotech com-
panies in Poland in 2010 was 49 with the employment reaching 3000 in total.
We argue that the Polish biotechnology industry is different from its Western European 
counterparts in important respects. There is both limited Big Pharma engagement and also lit-
tle venture capital investment. With respect to the latter, in late 2011 there were only two VC 
funds which specialized in life sciences, JCI Ventures and MCI BioVentures, which together 
own 11 portfolio companies including three DBFs. There are two foreign companies oper-
ating in the biotech industry in Poland. Over 50% of Polish DBFs are academic spin-offs. 
Since Poland’s accession to the EU in 2004, European funding has played an important 
role in the country’s overall development. The Innovative Economy Programme2, funded 
mainly by the European Regional Development Fund and managed by the Polish Agency 
for Enterprise Development (known as PARP in Polish3) is the main EU financial support 
mechanism for high-technology firms, including the biotech sector. Between 2007 and 2010 
Polish biotech firms signed public financing agreements worth PLN 139 million. This consti-
tutes, however, only 1% of the total value of agreements signed on behalf of the Programme, 
so that EU funds used to develop the Polish biotech industry have been minimal historically, 
although this source of funding is becoming much more significant particularly for the quot-
ed biotech SMEs.
Advantages enjoyed by the Polish biotech industry include importantly that the country 
benefits from a large and relatively well-developed network of medical schools and hospi-
tals. Consequently, Poland has a good track record as a competitive international destination 
for pre-clinical and clinical trials, with academic pharmacology and life sciences being of 
a high standard (Mroczkowski, Elms, 2009). Further positive features of the industry accord-
ing to the Europabio and Venture Valuation report (2009) include that the industry has an 
adequate science infrastructure. As examples of the latter, life science cluster initiatives have 
been established in Kraków, Wrocław and Gdańsk in addition to 30 science and technology 
parks in the country, and there has been a mushrooming of technology transfer offices at 
universities and R&D institutes. Accordingly, we argue that the potential for development of 
the industry is strong, but that actual development to date remains weak.
It is this background and the embedded three publicly quoted SME biotech firms by the 
end of 2010 that we explore using the following methodology.
2  The programme constitutes the largest source of funding for entrepreneurs who want to implement 
innovative R&D projects and use information and communication technologies. For the period 2007–2013 funding 
exceeds EUR 10 billion (85% of this amount coming from the European Regional Development Fund, with the rest 
originating from the state budget).
3  The Polish Agency for Enterprise Development (known as PARP in Polish) provides support to small 
and medium entrepreneurs. PARP aims to facilitate such matters as the use of innovative solutions by entrepre-
neurs, development of human resources, expansion in international markets and regional development, so improv-
ing the competitiveness of the Polish economy. In supporting entrepreneurs, PARP uses funds from both the state 
budget and the EU. For the period 2007–2013, PARP had responsibility for the implementation of measures un-
der three Operational Programmes, including Innovative Economy (Welcome to the Polish Agency of Enterprise 
Development, 2012. Retrieved April 25, 2012, from http://en.parp.gov.pl/.
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methodology
We follow Froud et al.’s (2006) narrative and numbers approach in constructing a case 
study of the biotech industry in Poland as a whole in distinction to their approach in which 
they analyse three individual multinational companies. Our narratives consist both of pub-
licly available press interviews in Polish as well as our own interviews with six key actors 
in the Polish biotech industry as at the end of 2010: entrepreneurs, representatives of biotech 
companies and institutions that support biotech industry. The focus of these interviews was to 
understand both institutional challenges and entrepreneurial behaviour in the Polish biotech 
industry. Additionally, we referred to other publicly available narrative information in both 
Polish and English.
Numbers used in constructing our case study of Polish biotech included our own da-
tabase of all DBFs, both public and private operating in the country, based on a variety of 
sources: the Hoppenstedt Bonnier database, companies’ websites and press interviews. The 
database details the following: the firm’s year of establishment, number of employees, found-
ers, owners and modes of establishment. Possible establishment modes consisted of Foreign 
Direct Investment (FDI), academic spin-off, spin-off from another company or change of 
profile from a firm that was previously non-biotech in character.
Finally, in order to ground our overall case of the Polish biotech industry in more de-
tailed empirical data, we focus on the three publicly quoted biotech SMEs as at the end 
of 2010. For this, we used publicly available information in both Polish and English. This 
included company annual reports and other periodical financial information (semi-annual, 
quarterly) and listing documents.
We use this multi-source methodology to situate the Polish biotech industry against the 
background of its institutional challenges.
InstItutIonal challenges facIng the PolIsh bIotech Industry
Poor linkages/cooperation between science and industry
In CE, research and science institutions are sometimes referred to as being like ‘ivory 
towers’ with limited contact with the business world (Mroczkowski, Elms, 2009). Similarly, 
Malo and Norus (2009) note that the modern biotech industry in Poland started mainly in in-
dustrial R&D institutes set up by communist ministries and science-funding bodies based in 
Warsaw and that, however well-funded, they never attained the level of sophistication found 
in public research organisations in more mature economies. Moreover, Malo and Norus 
(2009) cite Moore (2004) who writes about the poor legacy of misguided investment in 
Poland where as little as 20% of the entire public R&D budget was invested in life sciences. 
The situation has not changed significantly in recent years, since based on the general science 
budget for 2011, “natural sciences” R&D, a much wider category than biotechnology alone, 
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was due to received PLN 268 million (excluding EU co-funding), or about 22% of total 
R&D expenditure. Hence, a history of poor linkages between science and industry constitutes 
a major institutional challenge to the Polish biotech industry. This viewpoint is expressed by 
Professor Jan Lubiński, CEO of Read-Gene, a small quoted Polish biotech, in an interview 
published on 27/05/2009 on the biotechnologia.com.pl website: “We also need to change the 
way of thinking. We need to recognise the commercialisation of research as being something 
commendable, not questionable or controversial”. 
This is despite the large number of trained people, according to one of our interviewees, 
a biotech consulting micro firm owner, who are not willing to start a business. 
According to another of our interviewees, the project manager of one of the Polish ven-
ture capital funds: “There is a low willingness to spin-off in universities and a lack of entre-
preneurial culture, as for researchers only publications count. Researchers have an aversion 
to business. They would rather have 2 or 3 academic jobs instead – and so they end up having 
no time for starting their own businesses” (interview no. 2, 08/11/2010).
These attitudinal problems are compounded by problems related to patenting.
Patenting is expensive
Under communism, it was institutions rather than individuals who applied for patents 
in Poland. It is perhaps this legacy which explains why patenting is both time-consuming 
and expensive. Witek (2008) comments that at that time, for instance, a foreign patent ap-
plication and protection in PCT4 mode would cost 14,500–17,500 PLN, a sum 4.5–5.5 times 
the average monthly salary. To reinforce this point, a 10-year European Patent Office patent 
(covering 8 EU countries) would cost 57,000 EUR (238,140 PLN), or 62 times the average 
monthly salary.
 Moreover, in connection with patenting, the Europabio and Venture Valuation Report 
(2009) cites the lack of clear regulation of intellectual property rights (IPR) as constituting 
a major problem facing the Polish biotech industry. Indeed, most universities continue to 
retain rights to all research conducted both before and after patenting.
 Lack of life science policies
Mroczkowski and Elms (2009) describe Poland as following a more laissez-faire ap-
proach to the development of the biotech industry. This is in contrast for example to Hungary 
which has adopted a relatively well-funded national strategy of launching a biotech sector 
specialised in innovative drug discovery. Although the Polish government declared support 
for the sector in 2008 with its action plan for biotechnology, as of 2012 there is no clear 
government policy on biotech development. Previously established advisory bodies, such as 
the Interdisciplinary Bio-economy Development Team, have been disbanded and calls from 
the industry, requesting the creation of a national biotech development strategy following 
the more support-oriented Hungarian or Estonian models. Despite some regional and local 
4  A PCT application is an international application to protect inventions in one of the states that signed the 
Patent Cooperation Treaty (PCT).
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policy support, this lack of policy on the national level is well summarised by one of the di-
rectors of life science clusters, who said: “It is impossible to conduct life sciences in isolation 
from the rest of the world... The important problem in Poland is the lack of biotech-oriented 
funding policy” (interview no. 1, 25/10/2010).
Changing legal framework
One of the institutional challenges facing entrepreneurs in Poland relates to the con-
stant legal changes partly due to EU enlargement, which affect companies including biotech. 
These can be difficult to keep up with, something recognised in the operation from 2008 of 
the “Friendly State” parliamentary commission. This has as its aim the reform of unfriendly, 
unclear, inconsistent regulations that adversely affect entrepreneurial life. 
Given such institutional challenges, it is perhaps unsurprising that academics tend to 
create spin-off companies only rarely. There are some heritage reasons for this, as under 
communism running a business was almost impossible except in certain very special cir-
cumstances. To this can be added the continuing difficulties posed by university regulations 
which, according to Rogut and Cieślak (2009: 259), “are rigid and practically non-negotia-
ble, (so that) it becomes obvious why so many things are dealt with outside universities” 
rather than between university employees and firms.
Lack of sustainable funding
Biotechnology requires large public investment (Niosi, 2011) but deficiencies in nation-
al policy constitute a major reason behind the Polish biotech industry’s lack of sustainable 
funding. “It’s difficult to find funding and maintain R&D for a longer period of time” (inter-
view no. 5, biotech consulting micro firm owner, 10/02/2010).
Large-scale government funding tends to go to support substantial manufacturing pro-
jects rather than to knowledge-intensive industries, one interviewee commenting: “The gov-
ernment should change the direction of its investment as there is under-funding of science… 
30 million PLN for a T-shirt factory versus 2 million for R&D!” (interview no. 4, substantial 
private biotech firm spokesperson, 25/08/2010).
Looking at these institutional challenges we argue that they pose serious obstacles to the 
development of high technology and knowledge-intensive sectors. Given these institutional 
challenges we explore the applicability of Welter and Smallbone’s (2011) typology of entre-
preneurial behaviour to the case of biotech in Poland.
tyPes of entrePreneurIal behavIour In the PolIsh bIotechnology Industry 
Smallbone and Welter (2009a, b) and Welter and Smallbone (2011: 110) distinguish six 
types of entrepreneurial behaviour that are “distinctive responses to the external environment 
in which entrepreneurs were operating”. We argue that these responses, rather than being 
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distinctive, overlap to some extent. For instance, the fifth type , «networking» and personal 
contact for business purposes’ may easily overlap with other types. In summary, we argue 
that each entrepreneur exhibits a different combination of types of entrepreneurial behaviour. 
For instance, in Read-Gene there is an evidence of ‘prospective’ and ‘diversification of port-
folio’ behaviour with some signs of ‘financial bootstrapping’ at the time of the beginning of 
its operations.
While addressing entrepreneurial behaviour exhibited within the Polish biotech sector, 
we focus mainly on the three quoted SMEs as of the end of 2010 (see Appendix for sum-
mary details of these firms): Read-Gene, Euroimplant and Mabion. We also review further 
evidence of entrepreneurial behaviour discussed by other private companies we interviewed 
plus publicly available narratives on BioInfoBank5. 
Tab. 2. Typologies of entrepreneurial behavior
Types of entrepreneurial behaviour 
observed within the dimensions by 
current authors
Our dimensions 
of entrepreneurial 
behaviour
Types of entrepreneurial behaviour 
(Welter, Smallbone, 2011) observed 
within the dimensions
A B C
Adaptation strategy (A)
Active cooperation (B)
Open confrontation (C)
Regulations
(Tax) evasion (2)
Adaptation strategy (6)
Networking (5)
Prospecting behaviour (D)
Diversification and portfolio 
entrepreneurship (E)
Business
portfolio
Prospecting behaviour (1) 
Diversification and portfolio 
entrepreneurship (4)
Independent behaviour (F)
Investors cum ntrepreneurs (F1)
Single-person micro-firm (F2)
Funding Financial bootstrapping (3)
Source: own elaboration
As discussed earlier, we have identified three over-arching dimensions to Welter and 
Smallbone’s (2011) typology of entrepreneurial behaviour as shown in Table 2 above: reg-
ulations, business portfolio and funding (column B, Tab. 2). Column C represents the origi-
nal Welter and Smallbone typology grouped around the above-mentioned three dimensions. 
Column A represents individual behaviour types observed by the current authors in the bio-
tech industry within our three dimensions in column B. The relationship between the original 
Welter and Smallbone (2011) typology, our related dimensions and types of entrepreneurial 
behaviour observed within these dimensions by us is shown in Fig. 1 below.
5  BioInfoBank Institute is a hybrid non-profit organisation which undertakes applied R&D and which has 
also established a seed capital fund to create and support biotech initiatives. Additionally, the organisation has 
received over 10 grants conducted under EU Framework Programmes. The lengthy BioInfoBank case study is 
presented in what they call a ‘fairy tale’ narrative format on their website. We argue it constitutes an important 
and interesting case as it is claimed that PARP tried to engage in sabotage against some Polish biotech companies, 
including themselves.
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Fig. 1. Typologies of entrepreneurial behaviour and their inter-relationships
Source: own elaboration
entrePreneurIal resPonses towards regulatIons
We argue that a spectrum of companies’ attitudes towards regulations may be distin-
guished. Firms’ reactions to the challenging regulatory framework range from silent adapta-
tion to hostile responses that are based on direct confrontations with regulatory organisations. 
On this spectrum at least four types of entrepreneurial behaviour of biotech companies can be 
identified. The simplest behaviour, although not necessarily the cheapest by any means, is to 
adapt to existing regulations and associated organisational framework (Type A). BioInfoBank 
Institute (Bajka…, 2012) describes the case of a number of consultancies co-operating with 
PARP: “PARP was over-run by various consulting firms offering comprehensive support for 
grant application and handling. The same companies were engaged in organising conferenc-
es, training and inspection of projects, for which PARP was paying millions PLN. (…) The 
timeliness of payment transactions and the effectiveness of cooperation were supervised by 
PARP employees, who worked at the same time for consulting firms providing services to 
PARP and clients (author’s note summarising lengthy discussion by BioInfoBank. The main 
point is that this situation led to a serious conflict of interests on the part of some PARP 
employees)”.
We argue that despite these alleged problems in connection with PARP, some biotech 
firms are likely to have adopted an adaptation strategy (Type A of entrepreneurial behavior 
in Tab. 2 above) so as to increase their likelihood of obtaining grants.
Turning next to the biotech firms proper, some of the academic spin-offs find them-
selves needing to continue using such facilities as equipment and laboratories owned by 
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the original host university. This approach of active cooperation (Type B of entrepreneurial 
behaviour in Tab. 2) with host universities is to be seen in the Read-Gene case and that of 
Biocentrum, a private biotech firm. 
Due to the necessarily limited scope of the study, we were unable to uncover evidence 
of using personal contacts for business purposes. However, based on the biotech literature 
(e.g. Haslam et al., 2011), networking is crucial, but not necessarily in terms of exchange of 
favours and counter-favours and in dealing with authorities (Welter, Smallbone, 2011), but 
rather in co-operating as scientific colleagues.
Another type of entrepreneurial behaviour not identified by Welter and Smallbone (2011) 
concerns open confrontation with institutions and officials (Type C of entrepreneurial behav-
iour in Tab. 2), who “(…) do not understand the biotech industry” (to quote the spokesperson 
for a substantial private biotech firm (interview no. 4, 25/08/2010). We argue that such formal 
organisations as PARP may constitute indirect legacies of communism, given its rigidity and 
low understanding of the biotechnology industry. This applies even to organisations that are 
relatively newly established such as PARP, an arguably highly politicised agency in which 
managerial positions change with the advent of a new government. Because of such perceived 
deficiencies on the part of PARP, some organisations engage openly in a fierce struggle to 
obtain and retain funding from both agencies and ministries. Indeed, BioInfoBank decided to 
engage in an open confrontation with PARP. The founder of this highly successful organisa-
tion said in one publicly available interview: “We attempted to finance the company from the 
«Innovative Economy» Programme, but ended up going to court. (…)
I know of many firms that went bankrupt, because they were involved in the Innovative 
Economy Programme. (…) On the other hand, in highly subsidised industries, like biotech-
nology, you cannot compete without having a grant. If the owners are interested in such 
a high level of risk they could try to do so. (...) Unwillingness to cooperate on the part of 
PARP may lead to serious problems for companies” (Kuzdraliński, 2012).
Elsewhere, BioInfoBank criticise PARP and ministry officials for a lack of basic com-
petence and consequently lack of basic understanding towards biotech.
With respect to the Welter and Smallbone (2011) typology, due to both the limitations 
of our data and sensitivity of the topic, we have not uncovered any evidence for ‘tax evasion’ 
behaviour. In any case, this behaviour is less likely to be applicable to quoted biotech com-
panies which often do not pay taxes as they usually report losses during their early years.
Next, we posed the question as to how external factors influence entrepreneurial behav-
iour in terms of companies’ business portfolios.
entrePreneurIal behavIour In terms of busIness PortfolIos
Looking at Welter and Smallbone’s (2011) typology we agree that both types of en-
trepreneurial response (change and diversification of the company’s offering of products 
and services) are present in the biotech sector in Poland. ‘Prospecting’ behaviour (Type D) 
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does exist in the Polish biotech sector, although the change of products and services is not as 
frequent as in trade or manufacturing, due to the nature of the industry which involves large 
amounts of capital spend and lengthy product pipelines. However, biotech firms themselves 
are active participants in actually influencing the market in terms of new types of services 
and solutions offered. As an example of this behavior, Euroimplant has started selling a cos-
metics product, petals under the eyes, rather than concentrating purely on biotech proper. 
Some Polish biotech firms, therefore, tend to be highly flexible in their responses despite the 
rigidity constraints of the sector.
Another type of behaviour identified by Welter and Smallbone (2011) based on diversi-
fication of products (Type E) occurs in the early years of life of one of our cases, Euroimplant. 
The company reported relatively large revenues in 2007 that originated from renting out 
space and from consulting services rather than from its core biotech activities. This diversi-
fication of products or services presents a different case from one described by Welter and 
Smallbone (2011: 111), who write about entrepreneurs engaging in diversification in order to 
deal with problems of institutional deficiencies and corruption.
We have discussed earlier that the scarcity of sustainable funding in the Polish biotech 
industry poses a substantial institutional challenge. This then raises the question as to what 
types of behaviour in terms of funding strategies do Polish biotech firms follow?
entrePreneurIal behavIour In terms of fundIng strategIes 
Polish biotech SMEs rely heavily on their own resources for R&D, with nearly 60% of 
such expenditure of biotech firms in 2009 being self-funded (Nauka i Technika 2011 survey). 
Such an approach is summed up by Read-Gene’s CEO, who says: “We invested our own 
funds [in the company]. I put in almost all of my savings, and the operating costs were not in-
substantial” (Professor Jan Lubiński, CEO of Read-Gene, interview published on 27/05/2009 
on biotechnologia.com.pl website).
Other major funding sources in 2009 included EU funds, with structural funds and 
other EU funds contributing about 34.0% of total expenditures of biotech companies (Nauka 
i Technika, 2011). To quote the Raport (2007): “(...) the most important research in Poland is 
conducted based on EU money and grants from foreign universities” (Raport, 2007).
Among public SME biotechs, Mabion has received the largest amount of funds from 
the EU, with nearly 40 million PLN planned to be given from the Programme Innovative 
Economy between 2010 and 2014. Compared to Mabion’s 2010 revenue of 3.1 mln PLN, 
this is substantial. This is similarly true of Euroimplant for lab construction, and to a smaller 
extent, to Read-Gene.
Whilst EU funding is important, its impact should not be over-estimated. Importantly, 
EU funding is short-term compared to product development times within biotechnology. 
Moreover, such funding can also be unpredictable in timing and uncertain as the process of 
refunding investment from the EU is often delayed, one of the main reasons why Euroimplant 
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reported a net loss in 2010. Finally, there is also the danger that EU funds will have to be 
repaid later if associated conditions are not met.
Launching an Initial Public Offering (IPO) on the Warsaw Stock Exchange is becoming 
an increasingly popular source of funding. This is often vital as each company that applies 
for EU money has to prove it can contribute at least 25% of the costs to a project. With regard 
to this, Read-Gene’s CEO Professor Jan Lubiński says: “Money that comes from IPO and 
subsequent capital raises is necessary to launch some EU co-funded project” (Professor Jan 
Lubiński, CEO of Read-Gene, interview published on 04/092008 on www.inwestycjealter-
natywne.pl). 
Sometimes using funding from an IPO may be the only strategy to access finance and 
remain independent of both big pharma corporations or venture capital. Such ‘independent 
behaviour’ (Type F) is nicely summed up by Professor Jan Lubiński, who explains the rea-
sons why Read-Gene launched an IPO: “We decided in favour of an IPO because we were 
not treated well by the large capital providers. They wanted everything in return for nothing. 
They thought that we wouldn’t manage to raise any capital without them. They were wrong. 
An «ordinary Kowalski»6 trusted us and it worked out” (Professor Jan Lubiński, CEO of 
Read-Gene, interview published on 27/05/2009 on biotechnologia.com.pl website). 
The representative of one of the larger Polish private biotech companies summarises 
this as follows: “The company does not use venture capital – it’s difficult to sell to someone 
your own, authored idea” (interview no. 4, 25/08/2010). 
Moreover, Professor Jan Lubiński concludes that he: “(…) had a general feeling that 
venture capital funds intended to control the majority of shares but only in return for a small 
investment” (interview published on 04/09/2008 on www.inwestycjealternatywne.pl). 
This desire for independence suggests a self-confidence and wish for autonomy by the 
owner/researcher concerned and so contradicts to some extent with Sztompka’s (1996) com-
ments regarding the lack of independent behaviour rooted in the communist heritage.
This independent behaviour fits in well with the model observed in the Polish biotech 
sector where some companies (Selvita, a private firm as at end of 2010 and Euroimplant) 
operate in an ‘investor cum entrepreneur’ mode (see Fig. 1). For instance, Selvita was 
founded and has been managed by two IT engineers who invested their money earned in one 
of the largest software development companies in Poland for a promising biotech project. It 
is quite common for companies not only to use own financial resources of entrepreneurs, but 
to use EU funds as widely as it is possible (in particular to build lab infrastructure). For all 
three quoted biotech SMEs EU funding (pledged for varying periods from 2009 onwards) 
substantially contributes to the companies’ operations. EU funding therefore, whilst histori-
cally relatively insignificant, is becoming increasingly important to the development of quot-
ed biotech SMEs in Poland.
6  Kowalski is a common Polish surname similar to Smith in Anglo-Saxon countries. In making this com-
ment, Jan Lubiński means that small individual investors had faith in the firm’s IPO and so bought shares of the 
company. Importantly, the New Connect stock exchange on which Read-Gene floated its shares attracts mainly 
small investors.
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The other very common form of independence strategy, which is necessarily limited on 
an organisational scale, is to set up and run a single-person micro-firm, often by an aca-
demic (see Tab. 2). Such entrepreneurs treat their businesses as a source of extra income on 
top of their academic work and also: “profit from doing consultancy work” (interview no. 5, 
10/04/2010).
The same entrepreneur says he has: “(…) about more than a dozen small contracts per 
year” (interview no. 5, 10/04/2010). 
These micro-firms perform well – out of 21 SME Polish private biotech companies, 13 
reported profits in 2009 in contrast to the losses more usually reported by publicly quoted 
biotech firms. 
From our review of such funding strategies by Polish biotech entrepreneurs, we argue 
that these suggest a deep-seated desire for autonomy in the running of their businesses.
conclusIons
The key contribution of this paper is to have extended analysis of the Welter and 
Smallbone (2011) typology of entrepreneurial behaviour to the case of a knowledge-inten-
sive industry, biotech, in contrast to the majority of their examples which concerned man-
ufacturing and trade. Moreover, in our study we have contributed to the typology, the addi-
tional types of confrontation and independence. In our view, Poland does continue to repre-
sent a challenging environment at least for a knowledge-intensive industry such as biotech, 
because of its institutional challenges, which partly date back to its communist heritage. 
These include the poor linkages between science and industry and although newly estab-
lished, PARP’s rigidity and low understanding of biotech reminiscent of the communist era. 
We have argued that such institutional challenges provide a constraint on entrepreneurial 
behaviour.
The important question arises: to what extent the identified barriers are specific for the 
biotech industry, or do they apply for the whole Polish economy. When it comes to weak 
institutional framework it is a common feature many businesses must face up to in Poland. 
However, very low understanding of industry is more specific to a knowledge-intensive in-
dustry than a socialist legacy.
By discussing these institutional challenges, we have attempted to explain why the 
Polish biotech industry is not performing well relative to its potential.
With regard to the eight elements in the institutional structure of biotechnology distin-
guished by Bartholomew (1997), only a national tradition of scientific education is present. 
Other institutional aspects (e.g. the level and patterns of national funding of basic research 
and the degree of commercial orientation of R&D institutions, in particular) are lacking. 
The highly limited role of government in supporting the sector, expensive patenting and the 
changing legal framework cause the performance of the Polish biotech sector to lag behind 
its potential. In the absence of a flourishing venture capital sector, EU and own funding make 
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up most of the shortfall. However, we have argued that despite the institutional challenges 
facing the development of the biotech sector in Poland, we have uncovered evidence of inde-
pendent behaviour and a deep-seated desire for autonomy in the running of business on the 
part of some Polish biotech entrepreneurs.
Further research based on anonymous semi-structured interviews with entrepreneurs 
could explore other behaviours in the Welter and Smallbone (2011) typology, such as net-
working and more difficult to uncover issues such as tax evasion. Importantly also, further 
research should explore in greater depth from an institutional perspective, the applicability or 
otherwise of the Bartholomew elements of the biotech industry framework such as linkages 
to foreign research institutions and labour mobility to the Polish case, concerns which were 
outside the remit of the current study. Findings from such studies would have important pol-
icy implications for the development of the Polish biotech industry.
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Appendix. Comparative characteristics of the three Polish biotech SMEs quoted as at the end of 2010
Mabion Read-Gene Euroimplant
Profile
Oncology, development 
of humanised monoclonal 
antibodies (mAbs) 
technology
Methods of detection, 
prevention and treatment 
of the most common 
types of malignant 
tumours
Tissue engineering 
(epidermal grafts; 
cosmetic petals under the 
eyes). Composite collagen 
products
Employment 14 6 18
Year of 
establishment 2007 2005 2006
IPO date 2010 2009 2008 
Market value 
(mln PLN)*
94.53 62.49 83.96
IPO value (mln 
PLN)
1.9 in public offering, 
22.8 in private offering 
for shareholders before 
IPO
4.0 11.1
Revenue (2010, 
PLN)
3,084,918 363,643 721,423
Net profit/ (loss) 
(2010, PLN)
471,450 (399,200) (2,370,309)
Product/service
Generics + development 
of own products
Services + R&D Mass products + R&D
Ownership 
pattern
6 Polish pharma 
companies (including one 
VC)
Researcher – Professor 
Jan Lubiński
One quasi-venture 
capitalist + researcher + 1 
drug specialist
Main financial 
sources 
R&D in collaboration 
with scientific institutions 
+ creation of teams for 
particular research goals. 
Will buy/in-licence 
different technology as 
needed
Own R&D + Scientific 
collaboration + 
subcontracting.
Offers clinical trials to 
other companies
Own R&D financed 
largely by EU funds + 
scientific collaboration
Source: own elaboration based on companies’ annual reports, other periodical financial information (semi-annual, 
quarterly), listing documents and New Connect data
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